e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Biomarkers in asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy
A. Tam, S. J. Um, H. Coxson, S. Lam, S. Man, D. Sin (Vancouver, Canada)
Source:
Annual Congress 2013 –Biomarkers in asthma and COPD
Session:
Biomarkers in asthma and COPD
Session type:
Oral Presentation
Number:
397
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Tam, S. J. Um, H. Coxson, S. Lam, S. Man, D. Sin (Vancouver, Canada). Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy. Eur Respir J 2013; 42: Suppl. 57, 397
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Role of inflammatory biomarkers in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Sputum biomarkers of inflammation in smokers and subjects with COPD
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013
Endothelial microparticles in sputum of COPD patients: A potential biomarker of disease
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
COPD
Source: Respipedia Article
Year: 2018
Serum sirtuin-1 is reduced in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
L-arginine pathway metabolites can predict exacerbation independently from beta blocker treatment in patients with COPD: A follow-up study
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Increased circulating alveolar epithelial microparticles in COPD patients
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Changes of IL-6 level in bronchoalveolar fluid in patients with acute exacerbation of COPD before and after the treatment with tiotropium bromide, and its significance
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Alterations of the soluble proteome of airway epithelial cells in COPD
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Biomarkers in COPD exacerbation, the role of adiponectin
Source: International Congress 2014 – Predictors
Year: 2014
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept